Veltassa

(Patiromer)

ApprovedSmall molecule

Patiromer is used to treat high potassium levels in the blood by helping the body remove excess potassium through the digestive system.[2] Veltassa is currently approved and in use across 6 indications[4].[1]

Veltassa is one of 155 small molecule programs targeting Hyperkalemia. It is currently in Approved.

Indications

Total Trials

Active Trials

154

Competitors

Pipeline

Status by Indication[4][1]

Indication

HyperkalemiaActive, not recruiting

Diabetic NephropathyActive, not recruiting

Kidney DiseaseActive, not recruiting

Kidney TransplantActive, not recruiting

Heart FailureActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

HyperkalemiaPhase 3

Active, not recruiting

Diabetic NephropathyPhase 2

Active, not recruiting

Kidney DiseasePhase 3

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

Heart FailurePhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Veltassa

VVifor Pharma

Approved

3 2

Brethine

Sanofi

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

LCZ696

Novartis

Preclinical

15 5

Activase

Zemplar

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 8

Neo-Synephrine

EExela Pharma Sciences, LLC.

Sulfonylureas

1 10

Thiazolidinediones

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Chronic Kidney Disease

NCT06256991

Q4 2030

Phase 2Recruiting

Hyperkalaemia

NCT05766839

Clinical

Trials by Indication[1]

Hyperkalemia6 trials

Exploratory Study of ZG-801 for the Treatment of Hyperkalemia

Completed·ZZeria Pharmaceutical·Phase 2·NCT03799926·184 enrolled

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

Completed·DDominic Raj·Phase 2·NCT03326583·27 enrolled

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

Completed·RRelypsa, Inc.·Phase 3·NCT01810939·243 enrolled

Show 3 more trials

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

Completed·—·Phase 4·NCT03781089·36 enrolled

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

Completed·—·Phase 4·NCT02933450·43 enrolled

Patiromer With or Without Food for the Treatment of Hyperkalemia

Completed·RRelypsa, Inc.·Phase 4·NCT02694744·114 enrolled

Chronic Kidney Disease5 trials

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

Completed·NNYU Langone Health·Phase 4·NCT03183778·3 enrolled

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

Terminated·VVifor Pharma·Phase 2·NCT03087058·23 enrolled

Potassium Correction for RAAS Optimization in Chronic Kidney Disease

Recruiting·UUniversity Medical Center Groningen·Phase 4·NCT06256991·44 enrolled

Show 2 more trials

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

Completed·RRelypsa, Inc.·Phase 2·NCT03071263·295 enrolled

Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

Completed·RRelypsa, Inc.·Phase 2·NCT01130597·63 enrolled

Heart Failure3 trials

Evaluation of Patiromer in Heart Failure Patients

Completed·RRelypsa, Inc.·Phase 2·NCT00868439·120 enrolled

RELieving Increasing oEdema Due to Heart Failure

Terminated·NNHS Greater Glasgow and Clyde·Phase 4·NCT04142788·19 enrolled

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Completed·VVifor Pharma·Phase 3·NCT03888066·1,195 enrolled

Diabetic Nephropathy1 trial

Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)

Completed·RRelypsa, Inc.·Phase 2·NCT01371747·324 enrolled

Hemodialysis1 trial

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Terminated·RRelypsa, Inc.·Phase 2·NCT02033317·6 enrolled

6 more indications

MPA1 trial

Comparison of Potassium Binders in the ER

Terminated·UUniversity of California, Irvine·Phase 4·NCT04585542·37 enrolled

Renal Transplant Recipients1 trial

Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients

Completed·OOslo University Hospital·Phase 4·NCT05029310·13 enrolled

Kidney Disease1 trial

A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease

Completed·WWake Forest University Health Sciences·Phase 3·NCT03740048·51 enrolled

Dialysis1 trial

Patiromer and Diet/hrQoL in Chronic Dialysis

Recruiting· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT06858280·40 enrolled

Kidney Transplant1 trial

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

Completed·TThe Rogosin Institute·Phase 4·NCT03229265·8 enrolled

Hyperkalaemia1 trial

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Recruiting·VVifor Pharma·Phase 2·NCT05766839·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Patiromer. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Veltassa drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Patiromer compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Patiromer. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Vifor Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: VVifor Pharma

Veltassa

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2030

Trials by Indication[1]

Hyperkalemia6 trials

Chronic Kidney Disease5 trials

Heart Failure3 trials

Diabetic Nephropathy1 trial

Hemodialysis1 trial

MPA1 trial

Renal Transplant Recipients1 trial

Kidney Disease1 trial

Dialysis1 trial

Kidney Transplant1 trial

Hyperkalaemia1 trial

References

Drug Info

Quick Facts

Related News